[The association of intrathecal production of immunoglobulin free light chains and progression of multiple sclerosis]. 2017

G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
City Center of Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital #31, St. Petersburg, Russia; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia.

OBJECTIVE To assess an impact of immunoglobulin free light chains (FLC) on short-term and long-term prognosis of clinical and radiological activity and progression of disability in multiple sclerosis (MS). METHODS A sample of 381 patients with definite MS was divided into 2 groups. In group 1, lumbar puncture was performed at the time of clinically isolated syndrome, and patients were prospectively followed up to 2 years (short-term prognosis group, n=97). In group 2, MS was diagnosed immediately after lumbar puncture, and retrospective analysis of the disease course with the duration not less than 5 years was performed (long-term prognosis group, n=284). The Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score (MSSS) were used to assess patient's status. Concentrations of kappa and lambda FLC in the CSF (K-FLCCSF, L-FLCCSF) and serum (K-FLCSERUM, L-FLCSERUM) as well as quotients of concentrations (Q-K and Q-L) were determined. Patients were stratified into subgroups with high and low concentrations of K-FLC and L-FLC using cut-offs from our previous studies: K-FLCCSF=0.595 mcg/l and L-FLCCSF=0.127 mcg/l. RESULTS In group 1, significant correlations were found only between EDSS score and concentrations of K-FLCCSF (r=0.377, p=0.00019) and Q-K (r=0.366, p=0.0012). FLC concentrations did not correlate with the number of relapses and new T2 lesions. The age and EDSS score at the disease onset didn't differ between patients with high and low K-FLC and L-FLC (K-FLCCSF: р=0.2658; L-FLCCSF: р=0.5502). A significant decrease of EDSS score after the disease onset was observed in all groups except for patients with high concentrations of K-FLCCSF (p=0.1844), so the EDSS score after 2 years was significantly higher in this subgroup of patients (p=0.0006). In group 2, significant correlations of K-FLC with EDSS score (r=0.181, p=0.002) and MSSS score (r=0.121, р=0.044) for long-term prognosis (median (IQR) = 8 (6-13) years) were found. No correlations of FLC concentrations with the number of relapses during the first 5 years were found. Survival analysis showed that high concentrations of K-FLCCSF were associated with the high risk of progression to EDSS 6 (HR=2.055, p=0.026) but not with EDSS 4 (HR=2.388, p=0.08). CONCLUSIONS Concentrations of kappa FLC can help to define the prognosis of MS early at the disease course. Although low concentrations of FLC do not exclude a severe disease phenotype, patients with high K-FLCCSF concentrations are at greater risk for faster MS progression, probably, due to impaired reparation of neural tissue. Measurement of FLC concentrations can be used to determine a therapeutic tactics in patients with MS.

UI MeSH Term Description Entries
D007145 Immunoglobulin kappa-Chains One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa. Ig kappa Chains,Immunoglobulins, kappa-Chain,kappa-Immunoglobulin Light Chains,Immunoglobulin kappa-Chain,kappa-Chain Immunoglobulins,kappa-Immunoglobulin Light Chain,kappa-Immunoglobulin Subgroup VK-12,kappa-Immunoglobulin Subgroup VK-21,Chains, Ig kappa,Immunoglobulin kappa Chain,Immunoglobulin kappa Chains,Immunoglobulins, kappa Chain,Light Chain, kappa-Immunoglobulin,Light Chains, kappa-Immunoglobulin,kappa Chain Immunoglobulins,kappa Chains, Ig,kappa Immunoglobulin Light Chain,kappa Immunoglobulin Light Chains,kappa Immunoglobulin Subgroup VK 12,kappa Immunoglobulin Subgroup VK 21,kappa-Chain, Immunoglobulin,kappa-Chains, Immunoglobulin
D007146 Immunoglobulin lambda-Chains One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa. Ig lambda Chains,Immunoglobulins, lambda-Chain,Immunoglobulin lambda-Chain,lambda-1-Immunoglobulin,lambda-2-Immunoglobulin,lambda-Chain Immunoglobulins,lambda-Immunoglobulin Light Chain,lambda-Immunoglobulin Light Chains,lambda-x Immunoglobulin,Chains, Ig lambda,Chains, lambda-Immunoglobulin Light,Immunoglobulin lambda Chain,Immunoglobulin lambda Chains,Immunoglobulin, lambda-x,Immunoglobulins, lambda Chain,Light Chain, lambda-Immunoglobulin,Light Chains, lambda-Immunoglobulin,lambda 1 Immunoglobulin,lambda 2 Immunoglobulin,lambda Chain Immunoglobulins,lambda Chains, Ig,lambda Immunoglobulin Light Chain,lambda Immunoglobulin Light Chains,lambda x Immunoglobulin,lambda-Chain, Immunoglobulin,lambda-Chains, Immunoglobulin
D007147 Immunoglobulin Light Chains Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule. Ig Light Chains,Immunoglobulins, Light-Chain,Immunoglobulin Light Chain,Immunoglobulin Light-Chain,Light-Chain Immunoglobulins,Chains, Ig Light,Chains, Immunoglobulin Light,Immunoglobulins, Light Chain,Light Chain Immunoglobulins,Light Chain, Immunoglobulin,Light Chains, Ig,Light Chains, Immunoglobulin,Light-Chain, Immunoglobulin
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
September 1998, Acta neurologica Scandinavica,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
April 1991, Acta neurologica Scandinavica,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
January 2017, Annals of clinical biochemistry,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
November 2020, Scientific reports,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
November 2019, Clinica chimica acta; international journal of clinical chemistry,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
June 1998, Multiple sclerosis (Houndmills, Basingstoke, England),
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
January 1999, Neurologia i neurochirurgia polska,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
October 1985, Neurology,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
June 1987, Journal of neurology,
G S Makshakov, and V D Nazarov, and N A Totolyan, and S V Lapin, and A V Mazing, and V L Emanuel, and V S Krasnov, and M V Shumilina, and A A Skoromets, and E P Evdoshenko
January 2012, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Copied contents to your clipboard!